Plaintiff dismisses Vioxx law suit ahead of trial
Just five weeks before trial was set to begin in the Court of Common Pleas, Philadelphia County, Angela McCool voluntarily dismissed with prejudice her lawsuit against Merck & Co, in which she alleged that Merck & Co's withdrawn COX-2 inhibitor Vioxx (rofecoxib) had caused her husband's heart attack and death. The case was selected for trial by plaintiff's counsel and would have been the first Vioxx case to go to trial in Philadelphia.
"We believe that our evidence was strong in this case and Merck was prepared to go forward with the trial," said Ted Mayer of Hughes Hubbard & Reed, Merck's outside counsel.
In this case, Ms McCool alleged that Vioxx caused her husband's heart attack and death even though her husband experienced symptoms of heart trouble long before he took the drug and had several risk factors, including hypertension, high cholesterol and obesity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze